Literature DB >> 30416559

Role of Testosterone in the Treatment of Cardiovascular Disease.

Carolyn M Webb1, Peter Collins1.   

Abstract

Cardiovascular disease (CVD) is the most prevalent non-communicable cause of death worldwide. Testosterone is a sex hormone that is predominant in males but also occurs in lower concentrations in females. It has effects directly on the blood vessels of the cardiovascular system and on the heart, as well as effects on risk factors for CVD. Serum testosterone concentrations are known to decrease with age and reduced testosterone levels are linked to premature coronary artery disease, unfavourable effects on CVD risk factors and increased risk of cardiovascular mortality independent of age. A significant number of men with heart failure demonstrate reduced serum testosterone concentrations and there is early evidence suggesting that low testosterone levels affect cardiac repolarisation. Any association between endogenous testosterone concentrations and CVD in women has yet to be established. Testosterone replacement is used to treat men with hypogonadism but also has cardiovascular effects. This review will present the current evidence, expert opinion and controversies around the role of testosterone in the pathophysiology of CVD and surrounding the use of testosterone treatment and its effects on the cardiovascular system and CVD.

Entities:  

Keywords:  Testosterone; cardiovascular disease; men; risk factors; treatment

Year:  2017        PMID: 30416559      PMCID: PMC6223354          DOI: 10.15420/ecr.2017:21:1

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  67 in total

1.  Acute haemodynamic effects of testosterone in men with chronic heart failure.

Authors:  Peter J Pugh; T Hugh Jones; Kevin S Channer
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

2.  Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements.

Authors:  Hidetaka Hougaku; Jerome L Fleg; Samer S Najjar; Edward G Lakatta; S Mitchell Harman; Marc R Blackman; E Jeffrey Metter
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-09-13       Impact factor: 4.310

3.  Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.

Authors:  Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Circulation       Date:  2007-11-26       Impact factor: 29.690

4.  Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival.

Authors:  Ewa A Jankowska; Bartosz Biel; Jacek Majda; Alicja Szklarska; Monika Lopuszanska; Marek Medras; Stefan D Anker; Waldemar Banasiak; Philip A Poole-Wilson; Piotr Ponikowski
Journal:  Circulation       Date:  2006-10-09       Impact factor: 29.690

5.  Association Between Endogenous Testosterone and Cerebrovascular Disease in the ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Reshmi Srinath; Rebecca F Gottesman; Sherita Hill Golden; Kathryn A Carson; Adrian Dobs
Journal:  Stroke       Date:  2016-10-11       Impact factor: 7.914

6.  Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men.

Authors:  Marianna Yaron; Yona Greenman; Joseph B Rosenfeld; Elena Izkhakov; Rona Limor; Etty Osher; Galina Shenkerman; Karen Tordjman; Naftali Stern
Journal:  Eur J Endocrinol       Date:  2009-01-27       Impact factor: 6.664

Review 7.  EMAS position statement: Testosterone replacement therapy in the aging male‏.

Authors:  Christina Dimopoulou; Iuliana Ceausu; Herman Depypere; Irene Lambrinoudaki; Alfred Mueck; Faustino R Pérez-López; Margaret Rees; Yvonne T van der Schouw; Levent M Senturk; Tommaso Simonsini; John C Stevenson; Petra Stute; Dimitrios G Goulis
Journal:  Maturitas       Date:  2015-11-10       Impact factor: 4.342

8.  Lower testosterone levels predict incident stroke and transient ischemic attack in older men.

Authors:  Bu B Yeap; Zoë Hyde; Osvaldo P Almeida; Paul E Norman; S A Paul Chubb; Konrad Jamrozik; Leon Flicker; Graeme J Hankey
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

9.  Relationship of sex hormones to lipids and lipoproteins in nondiabetic men.

Authors:  S M Haffner; L Mykkänen; R A Valdez; M S Katz
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

10.  Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

Authors:  T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer
Journal:  Diabetes Care       Date:  2011-03-08       Impact factor: 19.112

View more
  4 in total

1.  Phthalates and Sex Steroid Hormones Among Men From NHANES, 2013-2016.

Authors:  Miriam J Woodward; Vladislav Obsekov; Melanie H Jacobson; Linda G Kahn; Leonardo Trasande
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 2.  Vascular Pathways of Testosterone: Clinical Implications.

Authors:  Margarida Lorigo; Melissa Mariana; Nelson Oliveira; Manuel C Lemos; Elisa Cairrao
Journal:  J Cardiovasc Transl Res       Date:  2019-12-09       Impact factor: 4.132

3.  An Observational Study of Hypertension and Thromboembolism Among Transgender Patients Using Gender-Affirming Hormone Therapy.

Authors:  Maria Pyra; Isabel Casimiro; Laura Rusie; Nat Ross; Cori Blum; Kristin Keglovitz Baker; Andie Baker; John Schneider
Journal:  Transgend Health       Date:  2020-03-16

Review 4.  Sex Differences in Adiposity and Cardiovascular Diseases.

Authors:  Haoyun Li; Daniels Konja; Luyao Wang; Yu Wang
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.